Theranexus (EPA:ALTHX) | WebDisclosure

Basculer en Français

9473	Companies
185399	Keywords
117755	Articles
99281	Press releases

Home
Companies
Theranexus

PRESS RELEASE

published on 04/23/2024 at 07:30, 1 year 7 months ago

Theranexus, Diverchim and Inserm awarded EUR 4.7 million in funding under the "Innovations in biotherapies and biomanufacturing" call for proposals from France 2030 to develop a novel antisense oligonucleotide
Theranexus, Diverchim, and Inserm's ARNA laboratory receive €4.7 million funding from French Government to develop autophagy activation therapy for rare neurological diseases under the PickASO project in collaboration with France 2030

Theranexus Diverchim Autophagy Activation Therapy Inserm PickASO Project
BRIEF

published on 04/18/2024 at 18:05, 1 year 7 months ago

Theranexus et BBDF annoncent des résultats positifs pour l'étude de phase 1/2 de Batten-1

Étude Clinique Maladies Rares Theranexus Maladie De Batten CLN3 Batten-1
BRIEF

published on 04/18/2024 at 18:05, 1 year 7 months ago

Theranexus and BBDF Announce Positive Results for Batten-1 Phase 1/2 Study

Clinical Study Rare Diseases Theranexus Batten-1 Batten Disease CLN3
PRESS RELEASE

published on 04/18/2024 at 18:00, 1 year 7 months ago

Theranexus et BBDF annoncent les données finales et positives de sécurité et d'efficacité de Batten-1 dans l'étude de phase 1/2
Theranexus et la Fondation BBDF annoncent des données positives sur la stabilisation des symptômes moteurs chez les patients jeunes adultes atteints de la maladie de Batten CLN3 après 18 mois de traitement

Theranexus Fondation BBDF Maladie De Batten Stabilisation Symptômes Moteurs Traitement Batten-1
PRESS RELEASE

published on 04/18/2024 at 18:00, 1 year 7 months ago

Theranexus and BBDF announce final and positive safety and efficacy data in the Phase I/II trial testing Batten-1
Theranexus and BBDF announce positive final results after 18-month Phase I/II trial of Batten-1 in juvenile Batten disease (CLN3) patients, showing stabilization of motor symptoms progression in young adults

Theranexus Batten-1 BBDF Juvenile Batten Disease Phase I/II Trial
PRESS RELEASE

published on 05/10/2023 at 16:59, 2 years 6 months ago

Theranexus et BBDF obtiennent l'accord de la FDA sur les critères d'efficacité de l'étude de phase 3 de Batten-1 dans la maladie de Batten CLN3

Accesswire

Published on 12/05/2025 at 02:35, 6 hours 14 minutes ago

Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 02:30, 6 hours 19 minutes ago

Klondike Gold Announces AGM Results
Published on 12/05/2025 at 01:00, 7 hours 49 minutes ago

BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 9 hours 44 minutes ago

BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 9 hours 49 minutes ago

NXT Energy Solutions Completes Data Acquisition for SFD Survey

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 08:30, 18 minutes ago

Dahua Technology Celebrates Pro Challenge 2025 to Deepen Global Installer Ecosystem Collaboration
Published on 12/05/2025 at 08:30, 19 minutes ago

Premier Miton Global Renewables Trust PLC - Suspension
Published on 12/05/2025 at 08:05, 43 minutes ago

Smartmi Unveils the Air Purifier 3: Powerful, Smart, and Stylish Air Care for Modern Homes
Published on 12/05/2025 at 08:01, 48 minutes ago

Original-Research: Warimpex Finanz- und Beteiligungsholding AG (von East Value Research GmbH ):
Published on 12/05/2025 at 08:01, 48 minutes ago

Custodian Property Income REIT plc: Interim results for the period ended 30 September 2025

Les Echos

Published on 12/05/2025 at 08:45, 4 minutes ago

Air Liquide va étendre et électrifier son unité de production d'oxygène à Shaanxi, soutenant ainsi l'engagement de la Chine à décarboner son industrie
Published on 12/05/2025 at 08:45, 4 minutes ago

Air Liquide to expand and electrify its oxygen facility in Shaanxi, supporting China’s commitment to decarbonize its industry
Published on 12/05/2025 at 08:42, 6 minutes ago

ENGIE - déclaration mensuelle du nombre total d'actions et de droits de vote composant le capital au 30 novembre 2025
Published on 12/04/2025 at 18:14, 14 hours 34 minutes ago

Résiliation d'une convention conclue entre actionnaires
Published on 12/04/2025 at 18:00, 14 hours 49 minutes ago

Informations relatives au nombre total de droits de vote et d’actions composant le capital social au 28 novembre 2025

View all LES ECHOS COMFI WIRE